Kairos Pharma (NYSE American: KAPA), a Los Angeles-based oncology therapeutics company, announced that its President and Chief Scientific Officer, Neil Bhowmick, will present and moderate at the 24th Annual Discovery on Target Drug Discovery Conference, held Sept. 28-Oct. 1 in Boston. Bhowmick will moderate a breakout session on Sept. 30 titled 'Winning the Race against Cancer Therapy Resistance,' focusing on Kairos' strategy of targeting cancer drug resistance to extend the efficacy of previously effective drug candidates. He will also deliver an oral plenary presentation on Sept. 30 at 2:35 p.m. Eastern on KROS-101, the company's drug candidate targeting solid tumors.
The presentation will center on KROS-101's targeting of GITR (Glucocorticoid-Induced TNF Receptor) to increase T-cell function and expand effector T-cells with anti-tumor activity. This approach is part of Kairos Pharma's broader mission to utilize structural biology to overcome drug resistance and immune suppression in cancer. The company's lead candidate, ENV-105, is an antibody that targets CD105, a protein identified as a key driver of resistance and disease relapse in response to standard therapy. ENV-105 aims to reverse drug resistance by targeting CD105 and restore the effectiveness of standard therapies across multiple cancer types.
The conference presentation is significant because it showcases Kairos Pharma's innovative research in a forum that brings together leading experts in drug discovery. By highlighting its strategy to combat therapy resistance, Kairos aims to attract attention from potential partners, investors, and the scientific community. For investors, the event could provide validation of the company's pipeline and potentially influence its stock performance. The latest news and updates relating to KAPA are available in the company's newsroom at https://nnw.fm/KAPA.
Kairos Pharma operates in a competitive landscape where overcoming drug resistance is a major challenge in oncology. The ability to extend the efficacy of existing therapies could have a substantial impact on patient outcomes and reduce healthcare costs. The company's focus on GITR and CD105 pathways represents a novel approach that, if successful, could lead to new treatment options for solid tumors and other cancers.
The announcement was distributed through NetworkNewsWire (NNW), a specialized communications platform focused on financial news and content distribution. NNW is one of 75+ brands within the Dynamic Brand Portfolio at IBN, which provides access to a vast network of wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution, and a full array of tailored corporate communications solutions. For full terms of use and disclaimers, see https://www.NetworkNewsWire.com/Disclaimer.
